Liquidia (LQDA) is back on investors’ radar after reporting fourth quarter 2025 results that included revenue of US$92.02 million and net income of US$14.56 million, in contrast with last year’s quarterly loss.

Despite the strong fourth quarter report, recent share price momentum has cooled, with a 7 day share price return of 5.01% and a 30 day share price return of 4.11%. At the same time, the 1 year total shareholder return of 145.51% and 3 year total shareholder return of more than 4x point to a powerful longer term rerating.

If Liquidia’s move has you thinking about other healthcare names tied to advanced treatments, it could be a good moment to check out 35 healthcare AI stocks

With shares up strongly over the past year but recent returns flattening, and analysts’ price targets and intrinsic estimates pointing to potential upside, the key question is whether Liquidia is still undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 17% Undervalued

With Liquidia last closing at $36.63 and the most followed narrative pointing to a fair value of $44.00, the gap between price and expectations is clear and raises the question of what is built into those forecasts.

In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $717.7 million, earnings will come to $299.9 million, and it would be trading on a PE ratio of 16.6x, assuming you use a discount rate of 7.0%.

Given the current share price of $32.15, the analyst price target of $44.0 is 26.9% higher. Read the complete narrative.

Curious what kind of revenue ramp, margin lift and earnings run rate are implied to support that price tag by the end of the decade? The projections rest on a sharp swing from losses to sizeable profits and a valuation multiple that lines up with broader US pharmaceuticals. To see how those ingredients fit together, it is worth walking through the full narrative that connects today’s price to those future cash flows.

Result: Fair Value of $44.00 (UNDERVALUED)

However, this story can change quickly if payer terms remain stricter for an extended period or if YUTREPIA demand falls short of the new manufacturing capacity being built.

Another Take: Multiples Paint A Tougher Picture

That $44.00 fair value from future earnings and cash flows suggests upside, but the current P/S of 20.4x is much richer than both the US pharmaceuticals industry at 4x and the fair ratio of 12x. That gap points to real valuation risk if sentiment cools before fundamentals catch up.

To see what the numbers say about this pricing gap in more detail, check the valuation breakdown through See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of strong recent results and richer multiples has stirred plenty of debate, so act while the data is fresh and shape your own view by weighing the 2 key rewards.

Looking for more investment ideas?

If Liquidia has sharpened your interest, do not stop here. Broaden your watchlist with other focused ideas that match different goals and risk levels.

• Target potential growth spurts by scanning for compact names that still meet quality filters through the 32 elite penny stocks with strong financials.
• Zero in on opportunities where quality and price work together by checking the 49 high quality undervalued stocks.
• Strengthen the foundation of your portfolio by finding financially resilient names through the solid balance sheet and fundamentals stocks screener (40 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.